TrialClinical pharmacology and therapeutics2020

Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients.

Amit Khatri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.